The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma: Current Status and Future Outlook
Open accessAbstract
Immunotherapy using autologous T cells has emerged to be a powerful treatment option for patients with metastatic melanoma. These include the adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs), T cells transduced with high-affinity T cell receptors against major tumor antigens, and T cells transduced with chimeric antigen receptors composed of hybrid immunoglobulin light chains with endodomains of T-cell signaling molecules. Among these and other options for T-cell therapy, TILs together with high-dose interleukin 2 have had the longest clinical history with multiple clinical trials in centers across the world consistently demonstrating durable clinical response rates near 50% or more. A distinct advantage of TIL therapy making it still the T-cell therapy of choice is the broad nature of the T-cell recognition against both defined and undefined tumors antigens against all possible major histocompatibility complex, rather than the single specificity and limited major histocompatibility complex coverage of the newer T cell receptors and chimeric antigen receptor transduction technologies. In the past decade, significant inroads have been made in defining the phenotypes of T cells in TIL-mediating tumor regression. CD8+ T cells are emerging to be critical, although the exact subset of CD8+ T cells exhibiting the highest clinical activity in terms of memory and effector markers is still controversial. We present a model in which both effector-memory and more differentiated effector T cells ultimately may need to cooperate to mediate long-term tumor control in responding patients. Although TIL therapy has shown great potential to treat metastatic melanoma, a number of issues have emerged that need to be addressed to bring it more into the mainstream of melanoma care. First, we have a reached the point where a pivotal phase II or phase III trial is needed in an attempt to gain regulatory approval of TILs as standard of care. Second, improvements in how we expand TILs for therapy are needed that minimize the time the T cells are in culture and improve the memory and effector characteristics of the T cells for longer persistence and enhanced anti-tumor activity in vivo. Third, there is a critical need to identify surrogate and predictive biomarkers to better select suitable patients for TIL therapy to improve response rate and duration. Overall, the outlook for TIL therapy for melanoma is very bright. We predict that TILs will indeed emerge to become an approved treatment in the upcoming years through pivotal clinical trials. Moreover, new approaches combining TILs with targeted signaling pathway drugs, such as mutant B-RAF inhibitors, and synergistic immunomodulatory interventions enhancing T-cell costimulation and preventing negative regulation should further increase therapeutic efficacy and durable complete response rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865 · cited 1×
“However, these CD8+ T cells have shorter telomeres and less T-cell costimulatory molecules causing them to be less able to undergo cell division following TCR stimulation than TEM cells.(100) They are also more sensitive to activation-induced cell death and cannot traffic to lymph nodes, and it is doubtful that they m…”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Cited by
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Chesney, J., Lewis, K. D., Kluger, H., Hamid, O., Whitman, E., Thomas, S., Wermke, M., Cusnir, M., Domingo-Musibay, E., Phan, G. Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005755 · Cited by 359
Andersen, R., Donia, M., Ellebaek, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hölmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1879 · Cited by 317
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827806e6 · Cited by 277
Immunotherapy in Melanoma: Recent Advances and Future Directions
Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023) · Cancers · doi:10.3390/cancers15041106 · Cited by 256
Therapeutic interventions for aging: the case of cellular senescence
Soto-Gamez, A., & Demaria, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.004 · Cited by 192
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107
“Whether ACT of TILs, an approach that can successfully mediate complete cancer regression in patients with metastatic melanoma (31, 32), can be developed for patients with metastatic GI malignancies has been little studied thus far (33).”
BackgroundZhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00805-x · Cited by 107
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Metadata
- Authors
- Wu, R., Forget, M.-A., Chacon, J., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G.
- Venue
- The Cancer Journal
- Published
- 2012-03
- Volume
- 18
- Issue
- 2
- Pages
- 160-175
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W2010205433
- Cited by
- 248
- References
- 16
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.